Repligen buys BioLife for $1.5 billion
Repligen Corp is acquiring BioLife Solutions in a deal valued at $1.5 billion.
The acquisition aims to expand Repligen’s presence in the cell therapy market.
The purchase price includes $11.25 in cash and 0.1442 shares of Repligen for each BioLife share, a 6.2% premium to BioLife’s last close.
The deal is expected to increase Repligen’s earnings and generate $20 million in savings by cutting costs.